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PCoronary Artery Disease
ngiotensin-Converting Enzyme
nhibitors in Coronary Artery Disease
nd Preserved Left Ventricular Systolic Function
Systematic Review and Meta-Analysis of Randomized Controlled Trials
ouaz H. Al-Mallah, MD,* Imad M. Tleyjeh, MD,† Ahmed A. Abdel-Latif, MD,‡
. Douglas Weaver, MD, FACC*
etroit, Michigan; Rochester, Minnesota; and Louisville, Kentucky
OBJECTIVES This study sought to assess the efficacy of angiotensin-converting enzyme inhibitors (ACEIs)
in patients with coronary heart disease and preserved left ventricular (LV) function.
BACKGROUND The ACEIs have been shown to improve outcomes in patients with heart failure and
myocardial infarction (MI). However, there is conflicting evidence concerning the benefits of
ACEIs in patients with coronary artery disease (CAD) and preserved LV systolic function.
METHODS An extensive search was performed to identify randomized, placebo-controlled trials of ACEI
use in patients with CAD and preserved LV systolic function. Of 61 potentially relevant
articles screened, 6 trials met the inclusion criteria. They were reviewed to determine
cardiovascular mortality, nonfatal MI, all-cause mortality, and revascularization rates. We
performed random-effect model meta-analyses and quantified between-studies heterogeneity
with I2.
RESULTS There were 16,772 patients randomized to ACEI and 16,728 patients randomized to placebo.
Use of ACEIs was associated with a decrease in cardiovascular mortality (relative risk [RR]
0.83, 95% confidence interval [CI] 0.72 to 0.96, p  0.01), nonfatal MI (RR 0.84, 95% CI
0.75 to 0.94, p  0.003), all-cause mortality (RR 0.87, 95% CI 0.81 to 0.94, p  0.0003),
and revascularization rates (RR 0.93, 95% CI 0.87 to 1.00, p  0.04). There was no
significant between-studies heterogeneity. Treatment of 100 patients for an average duration
of 4.4 years prevents either of the adverse outcomes (one death, or one nonfatal myocardial
infarction, or one cardiovascular death or one coronary revascularization procedure).
CONCLUSIONS The cumulative evidence provided by this meta-analysis shows a modest favorable effect of
ACEIs on the outcome of patients with CAD and preserved LV systolic function. (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.11.073Coll Cardiol 2006;47:1576–83) © 2006 by the American College of Cardiology Foundation
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Cngiotensin-converting enzyme inhibitors (ACEIs) have
een shown to be beneficial in patients with hypertension
1–3), those with recent myocardial infarction (MI) (4–8),
hose undergoing percutaneous coronary intervention (PCI)
9), and/or with left ventricular (LV) dysfunction (10–15).
n patients with congestive heart failure, analysis from the
tudies Of Left Ventricular Dysfunction (SOLVD) and the
urvival And Ventricular Enlargement (SAVE) trials sug-
ested that ACEIs may also reduce acute ischemic cardio-
ascular events by 20% (16–17). The current American
ollege of Cardiology and American Heart Association
uidelines for the management of ST-segment elevation
I recommend that an ACEI should be prescribed at
ischarge to all patients with ST-segment elevation MI
class I) (18). However, the evidence for routine adminis-
ration of ACEIs has been conflicting in patients with
oronary artery disease (CAD) with preserved LV systolic
From the *Division of Cardiology, Henry Ford Heart and Vascular Institute,
etroit, Michigan; †Department of Medicine, Mayo Clinic College of Medicine,
ochester, Minnesota; and the ‡Division of Cardiology, University of Louisville,
ouisville, Kentucky.2
Manuscript received August 2, 2005; revised manuscript received November 22,
005, accepted November 28, 2005.unction. Although two large trials (19–21) showed a
ecrease in cardiovascular death and nonfatal MI, no such
enefit was found in another large trial and in a few smaller
rials (22–26). We therefore performed a systematic review
f the literature and a meta-analysis of the efficacy of ACEIs
n patients with coronary heart disease and preserved LV
unction. We sought to determine the possible effect of
CEI therapy on all-cause mortality, cardiovascular mor-
ality, nonfatal MI, and revascularization rates in patients
ith CAD and preserved LV systolic function.
ETHODS
earch strategy. All randomized, placebo-controlled trials
f ACEIs use in patients with CAD and preserved LV
unction were identified using a two-level search strategy.
irst, we searched public domain databases, including Med-
ine (1966 to February 14, 2005), the Cochrane Central
egister of Controlled Trials (1st Quarter 2005), Database
f Abstracts of Reviews of Effects (1st quarter 2005),
ochrane Database of Systematic Reviews (1st quarter
005), Embase (1980 to 2005 week 6), U.S. Food and Drug
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April 18, 2006:1576–83 ACEI in CAD and Preserved LV Functiondministration website, and Biosis Previews (1969 to 2005
eek 8). We used the following key words: coronary artery
isease, myocardial infarction, and angiotensin-converting
nzyme inhibitors, as well as the following individual medica-
ions: captopril, cilazapril, enalapril, enalaprilat, fosinopril,
isinopril, perindopril, ramipril, and quinapril. Second, rel-
vant studies were identified through a manual search of
econdary sources, including references of initially identified
rticles and proceedings from national cardiology scientific
essions at the American Heart Association and American
ollege of Cardiology from 2001 through 2005. The search
as performed without any language restrictions. When an
bstract from a meeting and a full article referred to the
ame trial, only the full article was included in the analysis.
hen there were multiple reports from the same trial, we
sed the most complete and/or recently reported data.
nclusion and exclusion criteria. Reports of randomized
rials of ACEI use in patients with CAD and preserved LV
unction were eligible for inclusion in the meta-analysis.
andomized controlled trial was defined according to the
ational Library of Medicine criteria; CAD was defined as
istory of prior MI, percutaneous or surgical coronary
evascularization, angiographic evidence of atherosclerosis
n one or more major coronary arteries, or a positive stress
lectrocardiogram, echocardiogram, or nuclear stress test.
rials that enrolled patients with recent revascularization
ere included in the meta-analysis. Preserved LV systolic
unction was defined as an ejection fraction of40% and/or
bsence of clinical evidence of congestive heart failure. We
xcluded trials that did not have a placebo arm. We also
xcluded trials that had a follow-up duration of 2 years.
rials that did not report mortality, nonfatal MI, or revas-
ularization also were not included. Data for each trial were
bstracted by an investigator (M. A.) and confirmed by a
econd investigator (I. M. T.). All discrepancies were
dentified and resolved by consensus, or as needed, with a
hird investigator.
uality assessment. All eligible studies were assessed for
he following methodological quality criteria: generation of
llocation, allocation concealment, blinding of participants,
linding of caregivers, blinding of outcome assessment,
linding of data analyst, intention to treat analysis, and
ercentage of patients lost to follow-up (27).
tatistical analysis. The meta-analyses were performed by
omputing relative risks (RR) using a random-effects model
28). Quantitative analyses were performed on an intention-
o-treat basis and were confined to data derived from the
Abbreviations and Acronyms
ACEI  angiotensin-converting enzyme inhibitor
CAD  coronary artery disease
LV  left ventricular
MI  myocardial infarction
PCI  percutaneous coronary interventioneriod of follow-up. The RR for all-cause mortality, cardio- pascular mortality, nonfatal MI, and revascularization were
alculated along with the 95% CIs. The number needed to
reat to prevent one event was calculated by the inverse of the
ooled absolute risk reduction. Between-study heterogeneity
as analyzed by means of I2  [(Q df)/Q] 100%, where
is the chi-square statistic and df is its degrees of freedom.
his describes the percentage of the variability in effect
stimates that is caused by heterogeneity rather than sam-
ling error (chance) (29). Publication bias was assessed
raphically using a funnel plot. All analyses were performed
ith RevMan Analyses version 4.2.7 (2004, Cochrane
ollaboration, Oxford, United Kingdom). To explore het-
rogeneity, we conducted subgroup analyses, hypothesized a
riori, by using a statistical test of interaction (30). Studied
ubgroups included the study population (diabetes mellitus
DM] 20% vs. 20%) and outcome measures (systolic
lood pressure decrease 5 mm Hg vs. 5 mm Hg and
ollow-up duration 2 years vs. 2 years).
ESULTS
igure 1 shows the results of the literature search. From the
94 reports identified, 6 trials fulfilled the inclusion criteria.
e included the Heart Outcomes Prevention Evaluation
HOPE) trial in the meta-analysis even though only 80% of
hese patients had documented CAD because the rest of the
atients were at high risk for having CAD. We also
ncluded the Prevention of Atherosclerosis with Ramipril
rial (PART-2) for the same reason. We examined the
ffects of these two trials by sensitivity analysis. There were
3,500 patients enrolled in the seven trials, 16,772 in the
reatment arm and 16,728 in the placebo arm. The mean
ollow-up duration was 4.4 years.
Table 1 summarizes the baseline characteristics of the
atients. All patients were followed up for more than 2
ears. Patients enrolled in the HOPE trial were older, and
ore often were women and diabetic. On the other hand, a
istory of prior MI and prior revascularization were more
ommon among patients enrolled in the European Trial on
eduction of Cardiac Events With Perindopril in Stable
oronary Arteries (EUROPA) and Angiotensin-Converting
nzyme Inhibition in Stable Coronary Artery Disease
PEACE) trial. The use of evidence-based therapies (anti-
latelet agents, beta-blockers, and lipid-lowering therapies)
as highest among the recently published PEACE trial
atients.
The quality of the trials was assessed. Generation of
llocation and allocation concealment was adequate in most
f the trials. All trials were double blinded; however, the
linding of outcome assessment and blinding of data analyst
as not clear in all of the trials. All trials used an intention-
o-treat analysis.
The ACEI therapy resulted in a mean decrease of 3.9 mm
g in the systolic blood pressure and a mean decrease of 1.8
m Hg in the diastolic blood pressure. Data on bloodressure response to therapy were not available in the
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ACEI in CAD and Preserved LV Function April 18, 2006:1576–83uinapril Ischemic Event Trial (QUIET). Patients enrolled
n the HOPE and EUROPA trials had a larger decrease in
ystolic (4.1 mm Hg vs. 3.5 mm Hg) and diastolic (2.0 mm
g vs. 1.4 mm Hg) blood pressure. Only the PEACE and
OPE trials reported a decrease in new-onset diabetes over
he follow-up duration. Pooled data from both trials confirmed
he above observation (RR 0.76, 95% CI 0.60 to 0.95, p 
.02).
Figure 2 shows that ACEI therapy was associated with
decrease in cardiovascular mortality (RR 0.83, 95% CI
.72 to 0.96, p  0.01), nonfatal MI (RR 0.84, 95% CI
.75 to 0.94, p  0.003), all-cause mortality (RR 0.87,
5% CI 0.81 to 0.94, p  0.0003), and coronary
evascularization rates (RR 0.93, 95% CI 0.87 to 1.00, p
0.04). The combined data for coronary revasculariza-
ion were not available for the QUIET and PART-2
rials and were not included in the analysis. The number
eeded to treat with ACEIs to prevent either of the adverse
utcomes (one cardiovascular death or any death, or nonfatal
Figure 1. Search strategy results. RCT  randomized controlled trials.I, or revascularization) is 100. tThe test for heterogeneity showed no difference in effect
mong the studies as evident by I2 estimates for different
utcomes. The funnel plot shows symmetrical distribution
f RR estimates with no evidence of publication bias.
ensitivity and subgroup analyses. There was also a
trong trend toward decreased all-cause mortality (RR 0.89,
5% CI 0.77 to 1.02, p  0.09), even when combining data
rom the PEACE, QUIET, Effect of Antihypertensive
gents on Cardiovascular Events in Patients With Coronary
isease and Normal Blood Pressure Trial (CAMELOT), and
ART-2, which individually did not show any significant
eneficial effect of ACEIs. On the other hand, we found no
ignificant difference in nonfatal MI (RR 0.96, 95% CI 0.82
o 1.12, p  0.60), cardiovascular mortality (RR 0.87, 95%
I 0.58 to 1.30, p  0.5), or revascularization (RR 0.98,
5% CI 0.9 to 1.07, p  0.61).
We examined the effect of excluding the HOPE trial
rom the analysis because of its large weight in the pooled
stimate. The ACEI therapy was associated with a lower
ardiovascular death (RR 0.88, 95% CI 0.76 to 1.02),
ll-cause mortality (RR 0.89, 95% CI 0.81 to 0.98), revas-
ularization (RR 0.97, 95% CI 0.90 to 1.03), and nonfatal
I (RR 0.86, 95% CI 0.75 to 0.99).
Because absence of clinical evidence of heart failure is not
n adequate surrogate for preserved LV function, we per-
ormed another sensitivity analysis by excluding the EUROPA
nd PART-2 study. The combined estimates were: CV
eath, RR 0.85, 95% CI 0.69 to 1.05; all-cause mortality,
R 0.87, 95% CI 0.80 to 0.95; revascularization, RR 0.92,
5% CI 0.84 to 1.02; and nonfatal MI, RR 0.86, 95% CI
.72 to 1.03.
These point estimates obtained by different sensitivity
nalyses testing multiple assumptions remained consistent
ith the modest effect of ACEI similar to the primary
esults. However, they had wider confidence intervals be-
ause of the decrease in sample size when fewer trials were
ncluded.
Table 2 summarizes subgroup analyses. There was no
ignificant interaction between different outcomes and
ny of the studied subgroups: proportions of DM 20% vs.
20%, systolic blood pressure decrease 5 mm Hg vs. 5
m Hg, and follow-up duration 2 years vs. 2 years.
ISCUSSION
ased on the findings of this meta-analysis from more than
3,000 patients, our results confirm that ACEIs, when
dded to conventional therapy (aspirin, beta-blockers, and
tatins), are beneficial in patients with CAD and preserved
V function. Death, nonfatal MI, and the need for coronary
evascularization were all modestly reduced after ACEI
reatment. This benefit is, however, modest. Treatment of
00 patients for an average duration of 4.4 years prevents
ither of the poor outcomes (one death, or one nonfatal MI,
r one cardiovascular death or one coronary revasculariza-
ion procedure).
Table 1. Characteristics of the Trials Included in the Meta-Analysis
HOPE EUROPA PEACE QUIET PART-2 CAMELOT
Enrollment period 12/93–7/95 10/97–6/00 11/96–6/00 91–96 — 4/99–3/04
Publication year 2000 2003 2004 2001 2000 2004
Enrolling sites U.S., Europe, South
America, Mexico
Europe U.S., Canada, Italy U.S., Canada, Europe New Zealand U.S., Canada, Europe
ACEI Ramipril Perindopril Trandolapril Quinapril Ramipril Enalapril
Preserved LV definition EF 40% or clinical absence
of CHF
Clinical absence of CHF Echo, MPI preserved EF 40% Angiography, echo EF 40% Absence of
clinical CHF
EF 40%
CAD definition Documented CAD or “CAD
equivalent”*
Angiography, SE
(in men with CP)
MI, angiography Angiography MI, SE,
CVA†
Angiography
Primary end point CV death, MI, stroke CV death, MI, cardiac
arrest
CV death, MI, revascularization CV death, CV arrest, nonfatal
MI, revascularization or
hospitalization
Carotid intimal
thickening
CV death, CV arrest,
nonfatal MI,
revascularization,
CVA, PVD, or CV
hospitalization
Sample size 9,297 12,218 8,290 1,750 617 1,997
Mean follow-up (yrs) 4.5 4.2 4.8 yr‡ 2 4 2
Age (yrs  SD) 66  7 60  9 64  8 58 61 58
Women (%) 25 15 18 18 18 28
Prior MI (%) 53 65 55 49 42† 39
Prior PCI (%) 18 29 42 100 NA 29
Prior CABG (%) 26 29 39 NA NA 7
Hypertension (%) 47 27 46 47 Excluded 60
Diabetes (%) 38 12 17 16 8 18
Anti-platelets (%) 76 92 90 73 81 95
Beta-blockers (%) 40 62 60 26 43 77
Lipid-lowering therapy (%) 29 58 70 0.1 29 83
Calcium channel
blockers (%)
47 31 36 0 25 9
Diuretics (%) 15 9 13 NA NA 30
SBP/DBP lowering
(mm Hg)
3/2 5/2 3/1 NA 6/4 5/2
Percent on study drug at
3 yrs
71 81 75 76 74%§ Unknown
*The CAD equivalent patients had stroke, peripheral vascular disease, or diabetes plus at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low high-density lipoprotein cholesterol levels, cigarette
smoking, or documented microalbuminuria). †A total of 68% had CAD. ‡Median follow-up. §At 4 years.
ACEI  angiotensin-converting enzyme inhibitor; CABG  coronary artery bypass graft; CAD  coronary artery disease; CAMELOT  Effect of Antihypertensive Agents on Cardiovascular Events in Patients With Coronary
Disease and Normal Blood Pressure Trial; CHF  congestive heart failure; CP  chest pain; CV  cardiovascular; CVA  cerebrovascular accident; DBP  diastolic blood pressure; Echo  echocardiograph; EF  ejection fraction;
EUROPA  European Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Arteries trial; HOPE  Heart Outcomes Prevention Evaluation trial; LV  left ventricular; MI  myocardial infarction; MPI 
myocardial perfusion imaging; NA  not available; PART-2  Prevention of Atherosclerosis With Ramipril Trial; PCI  percutaneous coronary intervention; PEACE  Angiotensin-Converting Enzyme Inhibition in Stable Coronary
Artery Disease; PVD  peripheral vascular disease; QUIET  Quinapril Ischemic Event Trial; SBP  systolic blood pressure; SD  standard deviation; SE  stress echocardiography.
1579
JACC
Vol.47,No.8,2006
Al-M
allah
et
al.
April18,2006:1576–83
ACEI
in
CAD
and
Preserved
LV
Function
F
c
A
o
P

1580 Al-Mallah et al. JACC Vol. 47, No. 8, 2006
ACEI in CAD and Preserved LV Function April 18, 2006:1576–83igure 2. Pooled data from the included trials. The angiotensin-converting enzyme inhibitor (ACEI) therapy was associated with a decrease in
ardiovascular (CV) death (A), all-cause mortality (B), revascularization (C), and nonfatal myocardial infarction (MI) (D). CAMELOT  Effect of
ntihypertensive Agents on Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure Trial; EUROPA  European Trial
n Reduction of Cardiac Events With Perindopril in Stable Coronary Arteries trial; HOPE  Heart Outcomes Prevention Evaluation trial; PART-2 
revention of Atherosclerosis With Ramipril Trial; PEACE  Angiotensin-Converting Enzyme Inhibition in Stable Coronary Artery Disease; QUIETQuinapril Ischemic Event Trial; RR  relative risk.
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April 18, 2006:1576–83 ACEI in CAD and Preserved LV FunctionThe ACEIs have multiple potential cardioprotective
ffects. In addition to controlling blood pressure and
educing LV hypertrophy, they have multiple potential
nti-atherosclerotic effects. They improve endothelium-
ependent vasodilatation, and by increasing the level of
radykinin, increase the expression and activity of nitric
xide synthase and reduce the production of smooth muscle
roliferating agents (31–33). They are also associated with a
ecrease in vascular nicotinamide adenine dinucleotide ac-
ivity and reactive oxygen species. Use of ACEIs reduces
ctivation of important signaling pathways (including path-
ays involving nuclear factor-B and activator protein 1);
eductions in vascular inflammation, endothelial dysfunc-
ion, progression of atherosclerosis, and activation of met-
lloproteinases 2 and 9; an improvement in plaque stability;
decrease in the tendency toward thrombosis; and an
mprovement in fibrinolysis (34,35).
Each of the above changes could decrease cardiovascular
dverse events. However, not all of the individual trials
howed a statistically significant benefit of treatment. Mul-
iple reasons could explain this. Except for the CAMELOT
rial, all trials showed a reduction in all-cause mortality in
atients receiving ACEIs as evidenced by the individual RR
rom each study. However, this reduction did not reach
tatistical significance in some because of a small sample size
nd lack of statistical power. A meta-analysis can overcome
his limitation and detect smaller changes in outcome.
Differences in the risk profile and baseline therapies of
atients enrolled among different trials might have impacted
he final results by reducing event ratio. The baseline
haracteristics of the patients and adjunctive co-therapies in
he trials were consistently different. Patients in the HOPE
rial had the highest risk of cardiac events (older, and a
igher prevalence of female gender and diabetes). On the
able 2. Subgroup Analyses
Outcome
Relative Risk
95% Confidence
Interval
Patients With DM <20% of
the Sample Size
V mortality 0.76 0.65–0.87
onfatal MI 0.78 0.67–0.91
ll-cause mortality 0.89 0.78–1.02
evascularization 0.87 0.80–0.95
Follow-Up Duration <2 Yrs
V mortality 0.82 0.70–0.96
onfatal MI 0.85 0.74–0.97
ll-cause mortality 0.87 0.81–0.94
evascularization 0.94 0.87–1.01
SBP Decrease <5 mm Hg
V mortality 0.83 0.66–1.05
onfatal MI 0.88 0.69–1.12
ll-cause mortality 0.86 0.79–0.95
evascularization 0.93 0.82–1.05
bbreviations as in Table 1.ther hand, patients in the PEACE trial were more often on edjunctive therapies for CAD and had better risk factor
odification. Because relative risk estimates for all of these
roups were not available from the eligible trials, we were
ot able to explore heterogeneity because of the different
tudy populations. We attempted to explore heterogeneity
y using study-level data such as percent of the study
opulation with diabetes mellitus. This subgroup analysis
ay be underpowered to detect a difference.
The follow-up duration, which was not the same among
ifferent trials, can also explain between-study heterogene-
ty. The QUIET and CAMELOT trials, for example,
ollowed up patients for only two years, compared with the
OPE, EUROPA, and PEACE trials, in which follow-up
as four years or more. The beneficial effects of therapy
tarted after one year in EUROPA and two years in the
OPE trials. We did not find a statistically significant
nteraction between follow-up duration and effect size.
The fact that different ACEIs have different pharmaco-
inetic and pharmacodynamic characteristics is not a plau-
ible explanation because the majority of the patients re-
eived a tissue-specific ACEI. However, the dose of the
CEI was different among included trials. In the QUIET
rial, 20 mg quinapril did not affect the overall progression
f coronary atherosclerosis. This dose is less than “the
tandard” 40-mg dose most often used.
Another possible explanation of between-study heteroge-
eity might be related to differences in blood pressure
ecrease among different trials. Numerous experimental
tudies and clinical trials support the emerging realization
hat ACEIs restore endothelial function or prevent endo-
helial dysfunction more than what is expected from blood
ressure reduction alone (32). The HOPE and PEACE
rials were associated with the same degree of blood pressure
ecrease, yet the impact of ACEI treatment on the primary
Relative Risk
95% Confidence
Interval
p Value for
Interaction
Patients With DM >20% of
the Sample Size
0.89 0.75–1.05 0.16
0.86 0.74–1.01 0.38
0.89 0.81–0.98 1.00
0.97 0.91–1.04 0.05
Follow-Up Duration >2 Yrs
1.13 0.51–2.50 0.44
0.78 0.52–1.18 0.70
1.05 0.65–1.68 0.44
0.90 0.69–1.16 0.75
SBP Decrease >5 mm Hg
0.80 0.44–1.45 0.91
0.78 0.68–0.90 0.85
0.88 0.78–1.01 0.78
0.95 0.86–1.05 0.79nd point of both trials was different. Thus, the difference in
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ACEI in CAD and Preserved LV Function April 18, 2006:1576–83he magnitude of blood pressure decrease does not seem to be
he only reason for inconsistency between these two trials. In
ddition, subgroup analysis from HOPE and EUROPA indi-
ates that the benefits of ACEIs were universal in normoten-
ive as well as hypertensive patients (19,21).
Finally, there was a difference in the rate of statin use
etween the different trials. The ACEIs and statins inhibit
uperoxide production in the cell (36,37) and may have
imilar anti-inflammatory effects. Thus, a high statin use
ate may mask the anti-atherosclerotic benefit of an ACEI.
n the EUROPA trial subgroup analysis, the effect of
erindopril was independent of the use of statins. On the
ther hand, there was a trend toward benefit from
he ACEI inhibitor in patients who were not on statins in
he PEACE trial.
Our systematic review has several strengths. It helps to
nswer the general question of the beneficial effects of
CEIs in patients with CAD and preserved LV function
ith different treatment regimens. The findings in a ran-
omized clinical trial may be valid only for a population of
atients with the same characteristics as those investigated
n the trial. If many trials exist in different groups of patients
ith different co-treatments, with similar results in the
arious trials, then it can be concluded that the intervention
nder study has general applicability. In addition, by inte-
rating the actual evidence, our systematic review allowed a
ore objective appraisal of the literature by resolving un-
ertainties when the original randomized trial data did not
gree.
On the other hand, our analysis has possible limitations.
isease misclassification is a potential bias. Several studies
ave used a broad definition of preserved LV function and
AD (19,21). In addition, we did not have access to the
ndividual patient data, and we used the data in the
ublished manuscripts. Publication bias is another possible
imitation. Our process of literature identification was com-
rehensive and should have captured the majority of pub-
ished studies. There was no evidence of publication bias on
isual inspection of the funnel plot. We also searched for
npublished studies, and thus we think we have identified
ll relevant literature on this topic.
The results of this meta-analysis confirm the beneficial
ffects of ACEIs. This is in line with other meta-analyses
hat showed that ACEIs are useful in preventing new-onset
iabetes (38) and atrial fibrillation (39). However, these
eta-analyses included trials that also examined angiotensin
eceptor blockers. The current cumulative evidence supports
he use of an ACEI and should be considered in patients
ith pre-diabetic conditions, hypertension, impaired fasting
lucose levels, congestive heart failure, or coronary heart
isease.
In conclusion, our findings show that treatment with
CEIs, when added to conventional therapy, has a modest
ffect in reducing all-cause morality, cardiovascular mortal-
ty, nonfatal MI, and subsequent revascularization in pa-
ients with CAD who have preserved LV function.eprint requests and correspondence: Dr. Mouaz Al-Mallah,
enry Ford Heart and Vascular Institute, 2799 West Grand
oulevard, K 14, Detroit, Michigan 48202. E-mail: malmall1@
fhs.org.
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